Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine.
Drug addiction poses serious social, medical, and economic problems, but effective treatments for drug addiction are still limited. Cocaine and morphine elevate dopamine levels in the nucleus accumbens (NAc), and the overwhelming actions of dopamine are implicated in reinforcement and addiction of abusive drugs. In our previous studies, we reported the regulatory role of acetylcholine (ACh) in the NAc function by selectively ablating the NAc cholinergic neurons with use of immunotoxin-mediated cell targeting. These studies indicated that ACh and dopamine acted convergently but oppositely on the NAc circuit and that cholinergic cell ablation enhanced long-lasting behavioral changes of cocaine addiction. In this investigation, we showed that immunotoxin-mediated ablation of the NAc cholinergic neurons enhanced not only the sensitivity to morphine in conditioned place preference but also negative reinforcement of morphine withdrawal in conditioned place aversion. Remarkably, acetylcholinesterase (AChE) inhibitors that act on the brain AChE suppressed both cocaine- and morphine-induced conditioned place preference and blocked the induction and persistence of cocaine-evoked hyperlocomotion. Importantly, this inhibition was abolished by ablation of the NAc cholinergic neurons. These results demonstrate that centrally active AChE inhibitors prevent long-lasting behavioral abnormalities associated with cocaine and morphine addictions by potentiating the actions of ACh released from the NAc cholinergic neurons. Centrally active AChE inhibitors could thus be approached as novel and potential therapeutic agents for drug addiction.
Department of Biological Sciences, Kyoto University Faculty of Medicine, Japan.
Takatoshi
T
Hikida
Yasuji
Y
Kitabatake
Ira
I
Pastan
Shigetada
S
Nakanishi
D000109:Acetylcholine / Q000494:pharmacology*; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D003042:Cocaine / Q000494:pharmacology; D019970:Cocaine-Related Disorders / Q000517:prevention & control*; D003213:Conditioning, Psychological / Q000187:drug effects / Q000502:physiology; D000077265:Donepezil; D007189:Indans / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009020:Morphine / Q000494:pharmacology; D009021:Morphine Dependence / Q000517:prevention & control*; D009714:Nucleus Accumbens / Q000187:drug effects / Q000502:physiology*; D010146:Pain; D010880:Piperidines / Q000494:pharmacology; D013375:Substance Withdrawal Syndrome
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D009020:Morphine; D000077265:Donepezil; D003042:Cocaine; D000109:Acetylcholine